CORRECTION
Correction to: Adverse event management in the TOURMALINE-MM3study of post-transplant ixazomib maintenance in multiple myeloma
Martin Kaiser1,2 & Meral Beksaç3 & Nina Gulbrandsen4& Fredrik Schjesvold4
& Roman Hájek5 & Philippe Moreau6&
Felipe de Arriba de la Fuente7 & María-Victoria Mateos8 & Sharon West1 & Andrew Spencer9 & S. Vincent Rajkumar10 &
Kaveri Suryanarayan11& Michael Czorniak11 & Cong Li11 & Zhaoyang Teng11
& Richard Labotka11 &
Meletios A. Dimopoulos12
# Springer-Verlag GmbH Germany, part of Springer Nature 2020
Correction to: Annals of Hematologyhttps://doi.org/10.1007/s00277-020-04149-5
Low-resolution figures were inadvertently created during pro-duction and published. These have been replaced with thehigh-resolution figures that were originally provided by theauthors. No changes have been made to the data presentedwithin the figures or to any other manuscript content.
Please see below for the high-resolution figures:
The online version of the original article can be found at https://doi.org/10.1007/s00277-020-04149-5
* Martin [email protected]
1 Department of Haematology, The Royal Marsden Hospital,London, UK
2 Division of Molecular Pathology, The Institute of Cancer Research(ICR) and The Royal Marsden Hospital, 123 Old Brompton Road,London SW7 3RP, UK
3 Department of Hematology, Ankara University, Ankara, Turkey4 Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen
Center for B Cell Malignancies, University of Oslo, Oslo, Norway5 Department of Hematooncology, University Hospital Ostrava,
Ostrava, Czech Republic6 Department of Hematology, University Hospital Hôtel-Dieu,
Nantes, France
7 Servicio deHematología y OncologíaMédica, Hospital UniversitarioMorales Meseguer y Centro Regional de Hemodonación,IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
8 Department of Hematology, University Hospital of Salamanca, CIC,IBM CC, Salamanca, Spain
9 Malignant Haematology and Stem Cell Transplantation Service,Alfred Health-Monash University, Melbourne, Australia
10 Division of Hematology, Department of Internal Medicine, MayoClinic, Rochester, MN, USA
11 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary ofTakeda Pharmaceutical Company Limited, Cambridge, MA, USA
12 Hematology and Medical Oncology, Department of ClinicalTherapeutics, School of Medicine, National and KapodistrianUniversity of Athens, Athens, Greece
https://doi.org/10.1007/s00277-020-04302-0
Published online: 27 October 2020
Annals of Hematology (2021) 100:297–302
Fig. 1 CONSORT diagram.Reproduced with permissionfrom Dimopoulos MA, Gay F,Schjesvold F et al. Oral ixazomibmaintenance followingautologous stem celltransplantation (TOURMALINE-MM3): a double-blind,randomised, placebo-controlledphase 3 trial. Lancet2019;393:253–264
298 Ann Hematol (2021) 100:297–302
Months from date of first dose
0
2
4
6
8
10
12
14
16
18
20
0 5 10 15 20
Cum
ulat
ive
incid
ence
Placebo: All gradesPlacebo: Grade 3 or 4
Ixazomib: All gradesIxazomib: Grade 3 or 4
a
Total events
0
Frequency
No ac n takenDose held
Dose delayedDose reduced
Concomitant medica on administeredDose discon nued permanently
Dose increasedDose interrupted
Concomitant procedure performedDiscon nued from study
9242
2121
127
21000
25 50 75 0 25 50 75
84
03
0200000Ixazomib Placebo
c
160
Med
ian
plat
elet
resu
lt (1
09 /L)
170
180
190
200
210
220
386251
370242
354230
354231
349228
335217
340214
328205
321204
303196
291191
285185
282180
273181
268169
259165
251147
238142
239142
224135
232133
224126
216118
206112
193111
173104
361242
IxazomibPlacebo
SE
Visit
C25D1C2D1
C3D1C4D1
C5D1C6D1
C7D1C8D1
C9D1C10D1
C11D1C12D1
C13D1C14D1
C15D1C16D1
C17D1C18D1
C19D1C20D1
C21D1C22D1
C23D1C24D1
C26D1EOT
b
Fig. 2 Cumulative incidence ofnew-onset thrombocytopenia (a)and median platelet counts (b)over time in the ixazomib andplacebo groups, and actions takenfor events of thrombocytopenia(c). Note: More than one actioncould be taken for a single eventof thrombocytopenia
299Ann Hematol (2021) 100:297–302
Incid
ence
rate
(p
erpe
rson
*cyc
le)
IxazomibPlacebo
0
5Cycle
10 15 20 25
0.02
0.04
0.06
0.08
0.10
0.12
0.14
a
Incidence, n (%)Ixazomib (n=394)
Placebo (n=259)
0–3 months 73 (19) 16 (6)>3–6 months 28 (7) 12 (5)>6–9 months 15 (4) 6 (2)>9–12 months 15 (4) 4 (2)>12–15 months 10 (3) 2 (<1)
>15–18 months 2 (<1) 0
>18–21 months 7 (2) 0>21 months 4 (1) 0
Cum
ulat
ive
incid
ence
Ixazomib: All gradesPlacebo: All grades
00
Months from date of first dose5 10 15 20 25
4
8
12
16
20
24
28
32
36
40b
Fig. 3 Incidence rate by cycle (a) and cumulative incidence (b) of new-onset nausea. Only one patient in the ixazomib arm (< 1%) and nopatients in the placebo arm had grade ≥3 nausea. Incidence rate is the
number of events in a cycle divided by the sum of patient cycles at risk ina cycle. A patient with an ongoing AE could not be at risk of getting thesame AE until it was resolved
300 Ann Hematol (2021) 100:297–302
0
5Cycle
10 15 20 25
0.010.020.03
0.050.06
0.08
0.100.09
0.07
0.04
Incid
ence
rate
(p
erpa
tient
*cyc
le)
IxazomibPlacebo
a
Incidence, n (%)Ixazomib (n=394)
Placebo (n=259)
0–3 months 43 (11) 12 (5)>3–6 months 23 (6) 2 (<1)>6–9 months 8 (2) 4 (2)>9–12 months 15 (4) 4 (2)>12–15 months 5 (1) 4 (2)>15–18 months 5 (1) 0>18–21 months 4 (1) 2 (<1)>21 months 3 (<1) 0
Months from date of first dose25
00 5 10 15 20
369
12151821242730
Cum
ulat
ive
incid
ence
Ixazomib: All gradesIxazomib: Grade 3 or 4Placebo: All grades
b
Fig. 4 Incidence rate by cycle (a)and cumulative incidence (b) ofnew-onset vomiting. No patientsin the placebo arm had grade ≥ 3vomiting. Incidence rate is thenumber of events in a cycledivided by the sum of patientcycles at risk in a cycle. A patientwith an ongoing AE could not beat risk of getting the same AEuntil it was resolved
301Ann Hematol (2021) 100:297–302
Publisher’s note Springer Nature remains neutral with regard to jurisdic-tional claims in published maps and institutional affiliations.
Ixazomib
Placebo
0
5Cycle
Incid
ence
rate
(p
er p
erso
n*cy
cle)
10 15 20 25
0.01
0.02
0.03
0.05
0.06
0.08
0.10
0.09
0.07
0.04
a
00
Months from date of first dose
Cum
ulat
ive
incid
ence
5 10 15 20 25
4
8
12
16
20
24
28
32
36
40
Ixazomib: All Grades
Placebo: All GradesIxazomib: Grade 3 or 4
Placebo: Grade 3 or 4
Incidence, n (%) Ixazomib (n=394)
Placebo (n=259)
0–3 months 54 (14) 31 (12)>3–6 months 28 (7) 6 (2)>6–9 months 26 (7) 6 (2)>9–12 months 8 (2) 6 (2)>12–15 months 14 (4) 2 (<1)>15–18 months 2 (<1) 1 (<1)>18–21 months 2 (<1) 7 (3)>21 months 3 (<1) 2 (<1)
b
Fig. 5 Incidence rate by cycle (a) and cumulative incidence (b) of new-onset diarrhea. Incidence rate is the number of events in a cycle divided by thesum of patient cycles at risk in a cycle. A patient with an ongoing AE could not be at risk of getting the same AE until it was resolved
Incidence, n (%) Ixazomib (n=394)
Placebo (n=259)
0–3 months 37 (9) 23 (9)>3–6 months 12 (3) 5 (2)>6–9 months 12 (3) 6 (2)>9–12 months 4 (1) 2 (<1)>12–15 months 4 (1) 0>15–18 months 2 (<1) 2 (<1)>18–21 months 1 (<1) 1 (<1)>21 months 1 (<1) 0
Cum
ulat
ive
incid
ence
Months from date of first dose
00
2
4
6
8
10
12
14
16
18
20
5 10 15 20 25
Ixazomib: All grades
Placebo: All gradesPlacebo: Grade 2
Ixazomib: Grade 2Fig. 6 Cumulative incidence ofnew-onset PN. Only one patientin the ixazomib arm had grade 3PN (< 1%), and no patients ineither arm had grade 4 PN
302 Ann Hematol (2021) 100:297–302
Top Related